Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2023

Open Access 01-12-2023 | Biomarkers | Research

Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status

Authors: Xiao Liu, Shaomin Gong, Yichun Ning, Yang Li, Huili Zhou, Luna He, Lin Lin, Shi Jin, Ziyan Shen, Bowen Zhu, Fang Li, Jie Li, Xiao Tan, Xiaoyan Jiao, Yiqin Shi, Xiaoqiang Ding

Published in: BMC Nephrology | Issue 1/2023

Login to get access

Abstract

Background

Tubulointerstitial lesions play a pivotal role in the progression of IgA nephropathy (IgAN). Elevated N-acetyl-beta-D-glucosaminidase (NAG) in urine is released from damaged proximal tubular epithelial cells (PTEC) and may serve as a biomarker of renal progression in diseases with tubulointerstitial involvement.

Methods

We evaluated the predictive value of urinary NAG (uNAG) for disease progression in 213 biopsy-proven primary IgAN patients from January 2018 to December 2019 at Zhongshan Hospital, Fudan University. We compared the results with those of serum cystatin C (sCysC).

Results

Increased uNAG and sCysC levels were associated with worse clinical and histological manifestations. Only uNAG level was independently associated with remission status after adjustment. Patients with high uNAG levels (> 22.32 U/g Cr) had a 4.32-fold greater risk of disease progression. The combination of baseline uNAG and clinical data may achieve satisfactory risk prediction in IgAN patients with relatively preserved renal function (eGFR ≥ 60 ml/min/1.73 m2, area under the curve [AUC] 0.760).

Conclusion

Our results suggest that uNAG is a promising biomarker for predicting IgAN remission status.
Appendix
Available only for authorised users
Literature
1.
McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414–30.CrossRefPubMed
2.
O’Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the international kidney Biopsy Survey. Nephrol Dial Transplant. 2018;33(4):661–9.CrossRefPubMed
3.
4.
Natale P, Palmer SC, Ruospo M, Saglimbene VM, Craig JC, Vecchio M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020;3:CD003965.PubMed
5.
Xie J, Lv J, Wang W, Li G, Liu Z, Chen H, et al. Kidney failure risk prediction equations in IgA nephropathy: a Multicenter Risk Assessment Study in Chinese Patients. Am J Kidney Dis. 2018;72(3):371–80.CrossRefPubMed
6.
Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int. 2016;89(1):167–75.CrossRefPubMed
7.
Bazzi C, Rizza V, Olivieri G, Casellato D, D’Amico G. Tubular reabsorption of high, middle and low molecular weight proteins according to the tubulo-interstitial damage marker N-acetyl-beta-D-glucosaminidase in glomerulonephritis. J Nephrol. 2015;28(5):541–8.CrossRefPubMed
8.
9.
Lee HA, Seo YS. Current knowledge about biomarkers of acute kidney injury in liver cirrhosis. Clin Mol Hepatol. 2022;28(1):31–46.CrossRefPubMed
10.
Leung JCK, Lai KN, Tang SCW. Role of Mesangial-Podocytic-Tubular Cross-Talk in IgA Nephropathy. Semin Nephrol. 2018;38(5):485–95.CrossRefPubMed
11.
12.
Beker BM, Corleto MG, Fieiras C, Musso CG. Novel acute kidney injury biomarkers: their characteristics, utility and concerns. Int Urol Nephrol. 2018;50(4):705–13.CrossRefPubMed
13.
Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant. 2002;17(11):1890–6.CrossRefPubMed
14.
Machiguchi T, Yoshida H, Yonemoto S, Minakata T, Nomura K, Muso E, et al. Does circulating erythropoietin reflect progression of IgA nephropathy? Comparison with urinary N-acetyl-beta-D-glucosaminidase. Nephrol Dial Transplant. 1999;14(3):635–40.CrossRefPubMed
15.
Moresco RN, Speeckaert MM, Delanghe JR. Diagnosis and monitoring of IgA nephropathy: the role of biomarkers as an alternative to renal biopsy. Autoimmun Rev. 2015;14(10):847–53.CrossRefPubMed
16.
Pan P, Binjie H, Min L, Lipei F, Yanli N, Junwen Z, et al. A meta-analysis on diagnostic value of serum cystatin C and creatinine for the evaluation of glomerular filtration function in renal transplant patients. Afr Health Sci. 2014;14(4):1025–35.CrossRefPubMedPubMedCentral
17.
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification Working Group. Kidney Int. 2017;91(5):1014–21.CrossRefPubMed
18.
Gong S, Jin S, Li Y, Jiang W, Zhang Z, Shen Z, et al. Urinary soluble CD163 levels predict IgA Nephropathy Remission Status. Front Immunol. 2021;12:769802.CrossRefPubMedPubMedCentral
19.
20.
Zambrano S, He L, Kano T, Sun Y, Charrin E, Lal M, et al. Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing. Kidney Int. 2022;101(4):752–65.CrossRefPubMed
21.
Gewin LS. Renal fibrosis: primacy of the proximal tubule. Matrix Biol. 2018;68–9:248 – 62.
22.
Hsu CY, Xie D, Waikar SS, Bonventre JV, Zhang X, Sabbisetti V, et al. Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int. 2017;91(1):196–203.CrossRefPubMed
23.
Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019;179(7):942–52.CrossRefPubMedPubMedCentral
24.
Zhang J, Huang B, Liu Z, Wang X, Xie M, Guo R, et al. External validation of the International IgA Nephropathy Prediction Tool. Clin J Am Soc Nephrol. 2020;15(8):1112–20.CrossRefPubMedPubMedCentral
25.
Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol. 2019;23(1):26–31.CrossRefPubMed
26.
Siddiqui K, Al-Malki B, George TP, Nawaz SS, Rubeaan KA. Urinary N-acetyl-beta-d-glucosaminidase (NAG) with neutrophil gelatinase-associated lipocalin (NGAL) improves the diagnostic value for proximal tubule damage in diabetic kidney disease. 3 Biotech. 2019;9(3):66.CrossRefPubMedPubMedCentral
27.
Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis R. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177–83.CrossRefPubMed
28.
Rudnicki M, Siwy J, Wendt R, Lipphardt M, Koziolek MJ, Maixnerova D, et al. Urine proteomics for prediction of disease progression in patients with IgA nephropathy. Nephrol Dial Transplant. 2021;37(1):42–52.CrossRefPubMed
29.
Shi M, Ouyang Y, Yang M, Yang M, Zhang X, Huang W, et al. IgA Nephropathy susceptibility loci and Disease Progression. Clin J Am Soc Nephrol. 2018;13(9):1330–8.CrossRefPubMedPubMedCentral
30.
Ouyang Y, Zhao Z, Li G, Luo H, Xu F, Shao L, et al. A validation study comparing risk prediction models of IgA Nephropathy. Front Immunol. 2021;12:753901.CrossRefPubMedPubMedCentral
31.
Yu GZ, Guo L, Dong JF, Shi SF, Liu LJ, Wang JW, et al. Persistent hematuria and kidney Disease Progression in IgA Nephropathy: a Cohort Study. Am J Kidney Dis. 2020;76(1):90–9.CrossRefPubMed
Metadata
Title
Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status
Authors
Xiao Liu
Shaomin Gong
Yichun Ning
Yang Li
Huili Zhou
Luna He
Lin Lin
Shi Jin
Ziyan Shen
Bowen Zhu
Fang Li
Jie Li
Xiao Tan
Xiaoyan Jiao
Yiqin Shi
Xiaoqiang Ding
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Biomarkers
Published in
BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-023-03262-7

Other articles of this Issue 1/2023

BMC Nephrology 1/2023 Go to the issue

Research

Development of a clinical risk score system for peritoneal dialysis-associated peritonitis treatment failure

Research

The effect of intradialytic exercise on calcium, phosphorus and parathyroid hormone: a randomized controlled trial

Research

Systemic immune-inflammation index may predict the acute kidney injury and prognosis in patients with spontaneous cerebral hemorrhage undergoing craniotomy: a single-center retrospective study

Case report

Alport syndrome misdiagnosed with IgA nephropathy from familial history: a case report and brief review

Case report

Shift from severe hypotension to salt-dependent hypertension in a child with autosomal recessive polycystic kidney disease after bilateral nephrectomies: a case report

Research

Chronic kidney disease-related sarcopenia as a prognostic indicator in elderly haemodialysis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits